Pharmacyclics Inc.

    [td_text_with_title custom_title=”Company description”]Pharmacyclics, Inc. (Ticker: PCYC) a proud member of the AbbVie family, aiming to apply their combined scientific expertise, commercial experience, operational integrity, and organizational tenacity to help fulfill the company promise of providing targeted and patient-friendly therapies. Pharmacyclics believe in truly serving patients, their families, and caregivers.[/td_text_with_title]


    Ibrutinib is used to treat people with mantle cell lymphoma (MCL; a fast-growing cancer that begins in the cells of the immune system) who have already been treated with at least one other chemotherapy medication. It is also used to treat people with chronic lymphocytic leukemia (CLL; a type of cancer that begins in the […]

    [td_text_with_title custom_title=”Latest post”]

    AbbVie Completes Acquisition of Pharmacyclics

    NORTH CHICAGO, Ill., May 26, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc. enhancing AbbVie’s scientific and commercial presence in oncology. Pharmacyclics is a leader in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 […]

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]
    Pharmacyclics LLC
    Subsidiary of AbbVie
    Traded as Formerly NASDAQPCYC
    Industry Biopharmaceutical
    Founded 1991; 27 years ago (1991)
    Founders Jonathan Sessler, Richard A. Miller[1]
    Headquarters Sunnyvale, California
    Area served
    Key people
    Robert Duggan, former CEO and Chairman
    Parent AbbVie

    Pharmacyclics LLC is an American biopharmaceutical company based in Sunnyvale, California. It is primarily focused on the development of cancer therapies.[2][3] In 2017, Xynomic Pharmaceuticals acquired all global rights to Abexinostat, Pharmacyclics' primary commercial product.[4]

    Acquisition by AbbVie

    In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity.[5] The merger is expected to close in mid-2015.[6]

    Duggan will receive over $3.55 billion from the sale of Pharmacyclics to AbbVie in "one of the biggest paydays ever from the buyout of a publicly held company."[7][8][9][10][11]

    As CEO and Chairman of Pharmacyclics since 2008, Robert Duggan has opted not to receive compensation from the company.[12][7]


    1. ^ Lee Clippard (2006). "Professor's personal battle leads to development of new cancer drug". University of Texas. Retrieved May 30, 2015. 
    2. ^ Sawyer, Anthony (25 January 2018). "Pharmacyclics (PCYC) Given Daily Media Impact Score of 0.42". Week Herald. Retrieved 29 January 2018. 
    3. ^ "Pharmacyclics Inc. (PCYC)". Yahoo. Retrieved May 30, 2015. 
    4. ^ "Xynomic Acquires Global Rights to Anticancer Drug Abexinostat". Genetic Engineering & Biotechnology News. February 24, 2017. Retrieved February 25, 2017. 
    5. ^ Staff (5 March 2015). "AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21B". Genetic Engineering & Biotechnology News. 
    6. ^
    7. ^ a b "The $3.55 billion Man". America's Markets. 
    8. ^ Antoine Gara. "Robert Duggan". Forbes. 
    9. ^ "Pharmacyclics May Soon Be Acquired by Johnson & Johnson for $18 Billion". Science Times. 
    10. ^ "The Hiring Guru: Robert Duggan Billionaire". The Huffington Post. 
    11. ^ Sean Williams (27 February 2013). "This Is One Incredible CEO". 
    12. ^ Gary Strauss (March 24, 2015). "The $3.55 billion Man". USA Today. Retrieved May 29, 2015. 

    External links